Literature DB >> 20974848

IL-6-induced enhancement of c-Myc translation in multiple myeloma cells: critical role of cytoplasmic localization of the rna-binding protein hnRNP A1.

Yijiang Shi1, Patrick Frost, Bao Hoang, Angelica Benavides, Joseph Gera, Alan Lichtenstein.   

Abstract

Prior work indicates that IL-6 can stimulate c-Myc expression in multiple myeloma (MM) cells, which is independent of effects on transcription and due to enhanced translation mediated by an internal ribosome entry site in the 5'-UTR of the c-Myc RNA. The RNA-binding protein hnRNP A1 (A1) was also critical to IL-6-stimulated translation. Because A1 shuttles between nucleus and cytoplasm, we investigated whether the ability of IL-6 to enhance Myc translation was mediated by stimulation of A1 shuttling. In MM cell lines and primary specimens, IL-6 increased A1 cytoplasmic localization. In contrast, there was no effect on the total cellular levels of A1. Use of a dominant negative A1 construct, which prevents endogenous A1 from nucleus-to-cytoplasm transit, prevented the ability of IL-6 to enhance Myc internal ribosome entry site activity, Myc protein expression, and MM cell growth. IL-6-stimulated cytoplasmic localization was mediated by alterations in the C-terminal M9 peptide of A1, and this correlated with the ability of IL-6 to induce serine phosphorylation of this domain. A p38 kinase inhibitor prevented IL-6-induced A1 phosphorylation. Thus, IL-6 activates c-Myc translation in MM cells by inducing A1 phosphorylation and cytoplasmic localization in a p38-dependent fashion. These data suggest A1 as a potential therapeutic target in MM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20974848      PMCID: PMC3013026          DOI: 10.1074/jbc.M110.153221

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Aberrant translational control of the c-myc gene in multiple myeloma.

Authors:  F E Paulin; M J West; N F Sullivan; R L Whitney; L Lyne; A E Willis
Journal:  Oncogene       Date:  1996-08-01       Impact factor: 9.867

2.  Human hnRNP protein A1 gene expression. Structural and functional characterization of the promoter.

Authors:  G Biamonti; M T Bassi; L Cartegni; F Mechta; M Buvoli; F Cobianchi; S Riva
Journal:  J Mol Biol       Date:  1993-03-05       Impact factor: 5.469

3.  A nuclear export signal in hnRNP A1: a signal-mediated, temperature-dependent nuclear protein export pathway.

Authors:  W M Michael; M Choi; G Dreyfuss
Journal:  Cell       Date:  1995-11-03       Impact factor: 41.582

4.  Heterogeneous ribonucleoprotein A1 is part of an exon-specific splice-silencing complex controlled by oncogenic signaling pathways.

Authors:  N Matter; M Marx; S Weg-Remers; H Ponta; P Herrlich; H König
Journal:  J Biol Chem       Date:  2000-11-10       Impact factor: 5.157

5.  A mutation in the c-myc-IRES leads to enhanced internal ribosome entry in multiple myeloma: a novel mechanism of oncogene de-regulation.

Authors:  S A Chappell; J P LeQuesne; F E Paulin; M L deSchoolmeester; M Stoneley; R L Soutar; S H Ralston; M H Helfrich; A E Willis
Journal:  Oncogene       Date:  2000-09-07       Impact factor: 9.867

6.  The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism.

Authors:  Cynthia V Clower; Deblina Chatterjee; Zhenxun Wang; Lewis C Cantley; Matthew G Vander Heiden; Adrian R Krainer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-19       Impact factor: 11.205

7.  HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer.

Authors:  Charles J David; Mo Chen; Marcela Assanah; Peter Canoll; James L Manley
Journal:  Nature       Date:  2009-12-13       Impact factor: 49.962

8.  Interferons and interleukin-6 suppress the DNA-binding activity of E2F in growth-sensitive hematopoietic cells.

Authors:  D Melamed; N Tiefenbrun; A Yarden; A Kimchi
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

9.  Association of heterogeneous nuclear ribonucleoprotein A1 and C proteins with reiterated AUUUA sequences.

Authors:  B J Hamilton; E Nagy; J S Malter; B A Arrick; W F Rigby
Journal:  J Biol Chem       Date:  1993-04-25       Impact factor: 5.157

10.  The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation.

Authors:  W van der Houven van Oordt; M T Diaz-Meco; J Lozano; A R Krainer; J Moscat; J F Cáceres
Journal:  J Cell Biol       Date:  2000-04-17       Impact factor: 10.539

View more
  19 in total

1.  Heterogeneous nuclear ribonucleoprotein A1 is a novel cellular target of atrial natriuretic peptide signaling in renal epithelial cells.

Authors:  Bahar Hesabi; Robert S Danziger; Kumar U Kotlo
Journal:  Cell Signal       Date:  2012-01-17       Impact factor: 4.315

2.  MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.

Authors:  D-J Min; T Ezponda; M K Kim; C M Will; E Martinez-Garcia; R Popovic; V Basrur; K S Elenitoba-Johnson; J D Licht
Journal:  Leukemia       Date:  2012-09-13       Impact factor: 11.528

3.  ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.

Authors:  M R Yun; H M Choi; H N Kang; Yw Lee; H-S Joo; D H Kim; H R Kim; M H Hong; S O Yoon; B C Cho
Journal:  Oncogene       Date:  2017-09-25       Impact factor: 9.867

4.  IRES-dependent translation of egr2 is induced under inflammatory conditions.

Authors:  Daniela Rübsamen; Johanna S Blees; Kathrin Schulz; Claudia Döring; Martin-Leo Hansmann; Heinrich Heide; Andreas Weigert; Tobias Schmid; Bernhard Brüne
Journal:  RNA       Date:  2012-08-22       Impact factor: 4.942

5.  Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma.

Authors:  W-J Chng; G F Huang; T H Chung; S B Ng; N Gonzalez-Paz; T Troska-Price; G Mulligan; M Chesi; P L Bergsagel; R Fonseca
Journal:  Leukemia       Date:  2011-04-05       Impact factor: 11.528

6.  Genome-wide approaches to dissect the roles of RNA binding proteins in translational control: implications for neurological diseases.

Authors:  Katannya Kapeli; Gene W Yeo
Journal:  Front Neurosci       Date:  2012-10-02       Impact factor: 4.677

7.  Monoamine oxidase A expression is suppressed in human cholangiocarcinoma via coordinated epigenetic and IL-6-driven events.

Authors:  Li Huang; Gabriel Frampton; Arundhati Rao; Kun-song Zhang; Wei Chen; Jia-ming Lai; Xiao-yu Yin; Kimberly Walker; Brianne Culbreath; Dinorah Leyva-Illades; Matthew Quinn; Matthew McMillin; Michelle Bradley; Li-Jian Liang; Sharon DeMorrow
Journal:  Lab Invest       Date:  2012-08-20       Impact factor: 5.662

8.  Interleukin 6 downregulates p53 expression and activity by stimulating ribosome biogenesis: a new pathway connecting inflammation to cancer.

Authors:  E Brighenti; C Calabrese; G Liguori; F A Giannone; D Trerè; L Montanaro; M Derenzini
Journal:  Oncogene       Date:  2014-02-17       Impact factor: 9.867

9.  The long non-coding RNA GAS5 cooperates with the eukaryotic translation initiation factor 4E to regulate c-Myc translation.

Authors:  Guangzhen Hu; Zhenkun Lou; Mamta Gupta
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

10.  Protective Effects of Guava Pulp on Cholestatic Liver Injury.

Authors:  Jian Peng; Chunyan Yue; Kai Qiu; Jie Chen; Maria-Angeles Aller; Kwang Suk Ko; Heping Yang
Journal:  ISRN Hepatol       Date:  2013-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.